• Psychedelic drugs are on cusp of entering mainstream treatment for mental illness
• Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research
• Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra

A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by Cybin (NEO: CYBN) (NYSE American: CYBN). The psychedelic therapeutics company is joining forces with the Chopra Foundation to increase education and awareness of the potential use of psychedelics in supporting well-being and mental health (https://ibn.fm/IVdgc). “After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction,” the New York Times reported. “The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.” The article pointed to recent research by Rick Doblin, a pioneering psychedelics researcher, as evidence of that trajectory. “Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward . . . when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as ecstasy and molly,” the article stated. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder. “The results, coming weeks after a ‘New England Journal of Medicine’ study that highlighted the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms, have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine,” the article continued. “They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later.” This trend is almost certainly behind the new partnership between Cybin and the Chopra Foundation. Cybin has emerged as a leader in the psychedelic space, producing solid research indicating that psychedelic-assisted therapy can potentially improve the quality of life for people suffering with mental illnesses, including major depressive disorder, alcohol use disorder and anxiety disorders. The new partnership calls for the Chopra Foundation and Cybin to collaborate on efforts aimed to support education and awareness about groundbreaking research to harness the potential of psychedelic therapies in mental health. “The need for new and more effective treatments across the mental health spectrum is more urgent today than ever,” said Chopra Foundation founder, director and board chair Dr. Deepak Chopra. “Through our NeverAlone movement, we aim to combine forces with the best and brightest across businesses, policymakers, mental health professionals and others — all with the goal of building awareness, advancing scientific research and creating a global community to ensure widespread access to well-being resources. As the number of companies pursuing psychedelic-based therapies continues to grow, the foundation is particularly excited about partnering with Cybin based on its commitment to global well-being and mental health.” Noting that Cybin is one of the only companies that may truly address the needs of patients and providers, Chopra pointed out that “Cybin has cultivated a leadership position in this space based on their proprietary scientific approach that delivers the healing properties of classic psychedelics while reducing variable side effects that have prevented these natural compounds from becoming therapies in the past. . . . Their vision for improving the landscape of mental illness perfectly aligns with our goals, and we look forward to a productive partnership to further both of our missions.” Cybin CEO Doug Drysdale stated that the company is honored to partner with the Chopra Foundation and be part of the NeverAlone Initiative. “Much is understood about psychedelics, as they have been studied in academia for decades, but there is still much investigative work to be done,” he said. “At Cybin, we are using medicinal chemistry and drug-delivery technologies to build on existing clinical data and improve the patient experience by overcoming the limitations of current treatments for mental illness. We share the foundation’s pioneering spirit with regard to mental health and well-being and its goal of ensuring accessibility to much-needed treatment options to those in need.” For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

Companies and investors are invited to attend the Q1 2022 Virtual Investor Summit being held as a virtual event on March 8-9th, 2022.  The Investor Summit has been the largest independent conference on the East Coast for many years (formerly “The Microcap Conference”) and represents companies that are looking for a timely platform to connect with investors. The Q1 investor Summit focuses on connecting small and microcap companies with potential investors from large institutions, family businesses, private wealth and money managers. This Q1 conference will offer C level executives the opportunity to make presentations about the state of their business, updates on financials and future goals. Small and microcap companies can connect with investors through one-on-one discussions, presentations, and dialogues. “Our investors and presenting companies return to us repeatedly, owing to the immense response that they receive at these conferences.” Company Benefits 

• Scheduled meetings with qualified investors (average 8 per)
• 30-minute webcast with Q&A (average is 30+ attendees)
• Concierge meeting scheduling
• Press release distributed to the investor community in advance of the conference
• Webcast promoted on the conference website for 90 days post-conference
• Access to 800 registered attendees
• Media assets for social sharing
• Personalized tech training sessions

The Q1 Investor Summit 2022 will be organized as a virtual event with webcasts marketed on the website, giving companies optimum exposure. Investors can take part to listen to and meet and get a deep dive into potential stock investments. The seamless user experience offered at the event ensures that small-cap companies connect with investors and build long-term profitable business ties. The event has access to social media sharing, which gives the attending companies greater visibility. Connect with industry leaders and peers for a better knowledge, understanding, and higher ROI for presenting companies. To learn more, please visit https://investorsummitgroup.com/.

• Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use
• The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection
• Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals
• Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from the FDA

The recent announcement that drug bio-effectiveness innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology may be useful in erectile dysfunction therapy by enhancing the speed of effectiveness of medication sildenafil (common as Viagra) follows on a number of developmental successes reported by Lexaria. DehydraTECH is a proprietary technology that changes how the body detects and absorbs drugs by combining active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applying it to a food or other type of carrier particle, synthesizing it through a dehydration procedure and rendering the resulting powder or liquid as a final product capable of being rapidly absorbed by the body without suffering reduced effectiveness through filtration by the body’s liver and digestive system. Lexaria’s testing has focused on four basic areas of application — improving the treatment of heart disease and high blood pressure, delivering nicotine in a non-smoke form, improving the effectiveness of antiviral drugs and making CBD from hemp rapidly available without inhalation. During the company’s 2021-2022 study program (https://ibn.fm/Mm3SO) a number of successes have been reported. In the HYPER-A21-1 and 2 studies the company demonstrated enhancement in the amount of CBD delivered to lab animals’ bloodstreams and brain tissue, the HYPER-H21-1 and 2 studies showed improved blood pressure reduction and reduction of blood vessel stiffness in humans, and NIC-A21-1 revealed oral nicotine delivery peak levels that were 10 to 20 times faster and 10 times higher than those of the control substances. The series VIRAL-C21-3, VIRAL-A20-2, VIRAL-MC21-1, and VIRAL-A20-3 showed inhibition of the COVID-19/SARS-CoV-2 virus, increased drug availability, and potential FDA-compliant prevention of new molecular entity (“NME”) creation utilizing antiviral drugs Remdesivir, Ebastine and Colchicine. “Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website states (https://ibn.fm/LrsOC). “Lexaria licenses its advanced technology to other companies around the world to offer consumers the best performance possible across an array of product formats.” Currently, all of the company’s operations are fully funded through the second quarter of 2023. Revenues grew more than 150 percent between 2020 and 2021 as Lexaria uplisted to the Nasdaq Capital Markets. The DehydraTECH-CBD human studies for treating hypertension are the most advanced as the company is in preparations for an investigational new drug (“IND”) application with the aim of filing for a new drug application (“NDA”) with the FDA. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SaaS company SRAX offers a robust suite of cutting-edge products that facilitate engagement between public companies and investors, both existing and potential
• SRAX forecasts a record first quarter of $11.5 million in revenue as part of 2022 revenue in the range of $46-$48 million
• The company bought back ~$800,000 during Q2 2021, paid a dividend in January, and optimized its cap table via the elimination of an ATM filing

There are common fundamental threads between investing 30 years ago and today, but many things are extremely different. The digital age has changed everything, and fintech companies like SRAX (NASDAQ: SRAX) have their finger on the pulse of the new modality, where investors and companies alike are all-in on transparency, social media, and big data. SRAX, recognizing the challenges public companies face in engaging and attracting investors, amassed a suite of solutions to help connect public entities with investment communities. SRAX’s premier investor intelligence and communications platform, Sequire, is specialized to provide companies all the requisite tools necessary for a public company to thrive. The turnkey tech is designed to create long-term shareholders, host company events, communicate with stakeholders, and get in front of new potential shareholders via media campaigns and investment conferences. In September 2020, SRAX acquired LD Micro, a firm that is arguably the best known data and event company serving the small and micro-cap space. From its LD Micro Index to its data sets and ultra-popular events, LD Micro is synonymous with information. Every year, hundreds of companies and thousands of investors participate in the company’s conventions, either digitally or in-person. To that point, on January 27, the company’s 2022 Sequire Metals & Mining Conference was held. The preeminent virtual event (remaining digital in the covid environment) attracted 70+ premier metals and mining stock market companies and featured key opinion leaders for speeches and discussion panels. Investors can view replays of all the presentations here. Operations are delivering increasing sales, as evidenced by bookings meeting expectations for the fourth quarter of 2021 and full year 2022 guidance in the range of $46 million to $48 million. That’s up by approximately 50% from unaudited revenue of $31.5 million in 2021. Looking exclusively at the current quarter, SRAX forecast guidance of $11.5 million, more than doubling revenue from the quarter a year prior. “The nature of our annual contracts provides us exceptional visibility into revenue,” said Christopher Miglino, Founder and CEO of SRAX. “We are projecting that we will have our largest quarter ever in Q1 of 2022,” he added in providing the 2022 guidance. SRAX is executing on measures to build value for its shareholders. Last August, the company announced a new $10 million share repurchase plan, for which it bought-back about $800,000 worth of stock throughout the remainder of 2021 at an average price of $5.12 per share. Furthermore, SRAX made good on its promise to pay a dividend, giving SRAX shareholders preferred stock that translates to a cash payment or $0.01 per share. Additionally, Miglino said that the company eliminated their “At The Market” filing, a means of raising capital by selling new shares into the market, further optimizing the SRAX cap table as the company continues to look for opportunities to reward it shareholders. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Bitcoin locked on the Lightning Network has an estimated value of US$1.3 billion – indicating a bullish market contrary to the Bitcoin bear market
• LQwD has nodes active on the Lightning Network in the U.S., Germany, Singapore, and Indonesia, growing at an exponential rate by the day
• The Bitcoin Payment Ecosystem is expected to reach US$880 million by 2026
• LQwD launched its PaaS offering in November, aiming to facilitate payments worldwide

Bitcoin reached an all-time high of US$61,374.28 in October 2021, but since then the cryptocurrency’s value fluctuated significantly, dropping to US$37,928.58 in January 2022 (https://ibn.fm/OMawU). Throughout February, Bitcoin value continued to rise and fall, and it has been indicated that the cryptocurrency is currently a bear market. The same cannot be said about the Lightning Network, a layer 2 payment protocol that provides bitcoin scalability and instant transaction settlement across participating nodes with lower fees. The Network has reached an all-time high, with locked Bitcoin at an estimated value of US$1.3 billion, pointing to a bullish market for the Lightning Network (https://ibn.fm/sR2aj). One financial technology company, LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), is positioned to increase its nodes, channel, and overall value on the Lightning Network by creating an enterprise-grade infrastructure to drive bitcoin adoption as a platform-as-a-service (“PaaS”) provider. The company now has four nodes active on the Lightning Network – US-West, Germany, Singapore, and Indonesia, listed by age, oldest to newest.

• US-West: Active since October, US-West has seen some fluctuation but shows an overall 30-day upward trend. As of February 23, 2022, the node is listed with:
  • Current Capacity – 5.23134564 BTC (US$204,808.23)
  • Capacity Change (30-day) – 1.704466 BTC (US$66,797.58)
  • Current Channel Count – 91
  • Channel Count Change (30-day) – 22 (up 31.88%)
• Germany – Active since the beginning of February, LQwD’s Germany node has seen upward trending growth since going active. As of February 23, 2022, the node is listed with:
  • Current Capacity – 0.60500000 BTC (US$23,685.87)
  • Capacity Change (7-day) – 0.565000 BTC (US$22,115.5) up 1,412.50%
  • Current Channel Count – 15
  • Channel Count Change (7-day) – 11 (up 275%)
• Singapore – Also active since the beginning of February (released with Germany to expand global coverage), the Singapore node has seen great growth over a couple of weeks. As of February 23, 2022, the node is listed with:
  • Current Capacity – 0.82974242 BTC (US$32,484.58)
  • Capacity Change (7-day) – 0.719742 BTC (US$28,033.61) up 654.31%
  • Current Channel Count – 21
  • Channel Count Change (7-day) – 16 (up 320%)
• Indonesia – The Indonesian node is less than a week old, which does not provide substantial historical data to show an increase. The current capacity, channel count, and value of the node are:
  • Current Capacity – 0.07424242 BTC (US$2,906.61)
  • Current Channel Count – 1

The capacity of the nodes changes daily and can be monitored by visiting the Lightning Network Search and Analysis Engine https://1ml.com/. The Bitcoin Payment Ecosystem is expected to reach US$880 million by 2026, growing at a CAGR of 20.13% (https://ibn.fm/77Y3b). The adoption of digital wallets is expected to help drive these numbers as more people use cryptocurrency for making everyday purchases. The Lighting Network provides a platform for payments to be taken with ease – offering lower fees, quicker transaction times, and more scalability. The more nodes that come into play, the more options for international payment transfers – driving LQwD one step closer to becoming the top Lighting Network payment facilitator. LQwD released its dedicated PaaS, https://lqwd.tech/, in November 2021. The platform was designed to make access to the Lightning Network simpler and to accommodate more users looking for instantaneous transaction and settlement times, lower fees, and worldwide access to send and receive bitcoin payments. Using the LQwD platform does not require any special technical experience; it was built to be used by those who are just entering the bitcoin world, as well as by experts. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• The price of gold has increased by 6.5% to reach an 18-month high of $1,973.96
• Palladium has also increased by 5.1% in value for the third consecutive month
• Gold is proving to be the main safe-haven asset with the growing tensions
• StraightUp acknowledges a change in shareholders’ willingness to take more risks but looks to capitalize on opportunities that present themselves, specifically with the increase in the price of gold

Back in 2020, organizations worldwide had to deal with the pandemic and the geopolitical risk it presented. At that time, the situation affected investment and, more importantly, investors’ risk-taking appetite, mainly citing geostrategic, regulatory, and even political uncertainty (https://ibn.fm/6Tuu0). Fast forward to 2022, and the world is dealing with a whole different situation – the Ukraine crisis. While it is obviously focused on Eastern Europe, the evolving issue is affecting various sectors globally, and is not limited to the investment sector. StraightUp Resources (CSE: ST) (OTCQB: STUPF), an enterprise committed to mineral exploration and acquiring mineral property assets in North America, recognizes the issue and is opting to keep a close eye on the situation as it occurs. Despite its properties being located in North America, the developments in Russia and Ukraine, coupled with the former’s sanctions, are affecting its operations and its shareholders’ willingness to take more investment risks. Following the conflict, the price of gold and other precious metals has surged. Palladium, for instance, has seen a 5.1% increase in value for the third consecutive month, while gold has risen by 6.5%, reaching an 18-month high of $1,973.96 (https://ibn.fm/FCo6a). Gold has proven to be the main safe-haven asset with the growing tensions, surpassing cryptocurrencies and other assets such as Treasuries. Given that the shift for investment might understandably move more towards gold, it presents an opportunity for StraightUp, particularly since its properties are rich in gold deposits. For StraightUp, while the situation might cause fear of risk-taking, it can be expected to grow the demand for gold, increasing value for its shareholders. Everyone hopes that the situation gets resolved sooner rather than later. However, what remains certain is the impact it and other geopolitical situations around the world can have on markets and investing. StraightUp is keeping a close eye on the developments and remains focused on executing its plans for the 2022 calendar year, including new acquisitions and expansion of its market reach. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Fan Pass Live was released by Friendable in July 2020, and Artist Republik’s acquisition was completed in January 2022
• Friendable is positioned to leverage two markets – music streaming and music distribution services, capitalizing on technological advancements and the shift to digital platforms
• The global music streaming market was valued at $24.4 billion in 2020 and is expected to reach $76.9 billion by 2027
• The global music distribution services market was valued at $911.87 million in 2020 and is expected to reach $1.7 billion by 2030

In a movement of true independence for recording artists, Friendable (OTC: FDBL) is making a statement with its “anti-label” offerings – Fan Pass Live and the recently acquired Artist Republik. Three primary record labels rule the music industry – Sony Music, Warner Music, and Universal Music – each taking their revenue cut from the artists signed to them. The “anti-label” movement cuts out the contracts and high fees for distribution, leaving artists in control of their music once more. Released in July 2020, The Fan Pass Live artist platform is an online stage where artists can stream and perform music live for fans, all from a mobile device. The platform also offers artist channels, merchandise, and promotion options for artists without signing a recording contract. Fans pay a monthly subscription fee (which artists receive up to 40% of) for the Fan Pass Live experience. Additional revenue for artists comes from live show ticket sales, tips, merchandise sales and more! In January 2022, Friendable completed the acquisition of Artist Republik, a music distribution platform that provides independent artists access to all of the distribution services they would have with a recording company, without the contract. Artists can record, stream, and distribute their music without the restrictions of a recording label dictating their every move. With the combination of Fan Pass Live and Artist Republik, Friendable is creating a 360-degree all-inclusive music experience for artists worldwide. “With the decades-long struggle artists face due to the confines of a record label, along with the daily grind of finding income opportunities, we wanted to provide the opportunity for artists to regain control right from the start,” Friendable CEO Robert A. Rositano, Jr. said, according to an Instagram post celebrating the acquisition (https://ibn.fm/xt8il). Dean Rositano, President and CTO of Friendable, was quoted and says that with Artist Republik and Fan Pass Live, the company now has a 360 suite of products for independent artists to grow their fan base, as they augment their income streams, and continue engaging their fans without going the traditional route of a record label. Artist Republik Founder Nick Cianfaglione underlined that his platform single-handedly changed the face of independent music forever: “Now it’s time for us to partner with a powerful and well-resourced company, like Fan Pass, and combine forces to make double the impact in half the time.” Friendable has thus positioned itself to leverage two expanding markets – the music streaming market and music distribution services. The global music streaming market was valued at $24.4 billion in 2020 and is expected to reach $76.9 billion by 2027, growing at a CAGR of 17.8% from 2020 to 2027 (https://ibn.fm/xI3wa). The global music distribution services market was valued at $911.87 million in 2020 and is expected to reach $1.7 billion by 2030, growing at a CAGR of 6.2% from 2020 to 2030 (https://ibn.fm/vinDf). With the increase in technology and the demand for digital platforms, Friendable is staking its claim in both markets. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Knightscope’s shares began trading publicly on the Nasdaq Global Market on January 27, following the closing of a public offering that kicked off in early December
• Following the public offering, Knightscope has entered its 2nd chapter as it continues to work toward making the U.S. the safest nation in the world
• The company has now created a dedicated investor deck to help inform prospective and existing Knightscope investors

Roughly 90% of women and 60% of men visit companies’ investor relations (“IR”) websites when researching a new investment opportunity. These statistics, uncovered by PR Newswire’s Vintage Division in its 2016 Shareholder Confidence 365 Study (https://ibn.fm/Ky87z), are complemented and reinforced by insiders’ observations that a company’s IR website is one of the most important sources of information for investors (https://ibn.fm/tz4QR). The IR website, they say, should not be overly complex. Instead, it should have user-friendly navigation, with key content reachable using just a few clicks, and offering simple data summaries. dTo this end, Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies, has rolled out a dedicated simplified IR site (https://ibn.fm/ihdBE) linking directly to the company’s investor presentation and CEO’s video introduction to the latest shareholder meeting. This site augments Knightscope’s general investor overview information offered as a tab on the company’s main website, featuring Knightscope’s story, investor updates, news, events, presentations, corporate governance, financial information, stock information, and IR resources. Knightscope’s shares were first announced to be listed on the Nasdaq Global Market in early December (https://ibn.fm/lkMjS), kick-starting a public offering that raised over $22.3 million through the sale of 2,236,619 shares of the company’s Class A Common Stock as of January 26 (https://ibn.fm/VKcQ3). Trading on NASDAQ commenced on January 27, 2022. “We’ve brought on thousands and thousands of new investors in Knightscope as we embark on the 2nd chapter of a very long book in helping to make the United States of America the safest country in the world. I am forever grateful for our relentless team and the 28,000+ investors that helped write the 1st chapter in our journey,” commented Knightscope Chairman and CEO William Santana Li following the closing of the public offering. The company intends to direct the net proceeds of the offering toward the scaling of its current fleet of Autonomous Security Robots (“ASRs”), which includes the K1, K3, and K5, as well as simultaneously investing in new technologies. With these proceeds, Knightscope’s 2nd chapter appears well underway, driven by investors, for whom the intuitive, simple, well-structured, and informative IR website is intended. Since its inception in 2013, Knightscope has leveraged investments from its supporters – to the tune of more than $100 million, according to its latest presentation (https://ibn.fm/3umH7) – with the amount going toward building all the crime-fighting technology from scratch. In addition to its ASRs, the company also offers the Knightscope Security Operations Center (“KSOC”) user interface, data storage, analytics, and charging systems, which are collectively anchored in a Machine-as-a-Service business model. The KSOC user interface enables security professionals to monitor multiple locations, manage patrol schedules, sound alarms, communicate via two-way intercoms, as well as watch and listen to the happenings around the ASRs. Knightscope has a recurring revenue business model for a recurring societal problem of crime, and is well poised to continue to grow with its portfolio of advanced physical security technologies. For more information about Knightscope (NASDAQ: KSCP), visit the company’s website at www.Knightscope.com, and if you have a need for a subscription service, you may request a private demonstration of the technology at www.Knightscope.com/demo.  NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Company announced the first officially issued patent
• Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds
• CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences

In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of classical psychedelics, while addressing the known limitations necessary for these molecules to become approvable therapeutics,” said Cybin CEO Doug Drysdale. “We are extremely pleased to receive a composition of matter patent for CYB004, adding strong protection for our growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments that we are making in our CYB004 program. This patent is both rewarding and timely as we prepare to initiate a pilot study for CYB004 in the third quarter of 2022 and work tirelessly to develop an important and alternative treatment option for the millions of people suffering from anxiety disorders.” Under the patent, allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT; the patent also covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity until 2041, when the patent is set to expire. Most importantly, perhaps, the patent highlights the strength of Cybin’s IP position and the company’s differentiated approach to bringing a psychedelic-based therapy toward regulatory approval and to patients in an otherwise congested industry. Cybin has spent considerable time and resources developing CYB004, which has the potential to effectively treat anxiety disorders with improved control over DMT delivered through inhalation. Specifically, in preclinical trials, the proprietary DMT compound indicated reduced dosage for better safety as well as the potential for longer duration of effect while reducing negative experiences associated with current treatment methods. For more information on Cybin’s programs, visit their corporate presentation at the following link: https://ibn.fm/RzdzR. Looking forward, the company is planning a pilot study of CYB004; Cybin intends to submit a clinical trial application for the study in coming weeks with expectations to begin the study in Q3 of 2022. In addition, Cybin will follow up on multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses. The market for Cybin’s newly patented CYB004 is vast, with the National Institute of Mental Health reporting that an estimated 19% of adults in the United States had any anxiety disorder in the past year and more than 31 of U.S. adults will experience any anxiety disorder at some point in their lives). With those numbers as a backdrop, the potential is high for Cybin’s innovative drug-delivery systems to change lives and establish the company as a leader in a billion-dollar industry Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• PlantX launched XFitness, an online fitness service that will be exclusive to XVIP members
• The service features classes that accommodate people from all age groups and can be enjoyed either individually or as a group
• XVIP members will also enjoy discounts on the PlantX store, free shipping, and premiere access to the company’s special events and product launches, among other perks
• PlantX also announced the completion of an oversubscribed non-brokered private placement of 52,296,660 units of the company at CAD$0.105 per unit

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), since its inception, has remained committed to being the digital face of the plant-based community. In addition to over 5,000 plant-based products in its portfolio, the company also seeks to educate its consumer base while also engaging in community-building efforts. Its efforts are geared towards enriching people’s lives, growing and empowering the plant-based community. In a recent move that affirms this commitment, PlantX announced the launch of its new online fitness service- XFitness. This service will cover programs and activities that include but are not limited to cardio, yoga, high-intensity interval training, meditation, boxing, martial arts, strength-based and functional fitness (https://ibn.fm/wi1he). This new program will be accessible to XVIP members, a newly-launched membership program that opens PlantX customers to a growing list of benefits and exclusive membership offers. These benefits include PlantX coupon codes, 5% off all purchases on the PlantX platform, and 10% off when using an instructor coupon code. XVIP members will also enjoy free shipping on all PlantX orders, in addition to premier access to the company’s special events and product launches. “We have created PlantX to be a plant-based brand and our vision aims to enrich people’s lives not just through plant-based education, but also by promoting general health, fitness and wellness,” noted Sean Dollinger, the Founder of PlantX. “The XFitness vertical is a crucial component of this vision, as it helps our community gain access to fun and interactive fitness classes, connect with like-minded individuals and learn how to create an integrated plant-based routine to enhance their overall health and wellbeing,” he added. XFitness classes are structured to accommodate people from all age groups, including children and the youth. It is also an adaptable fitness platform where members can enjoy and participate individually or as a group. The goal is to have PlantX customers access high quality, fun, and effective fitness resources, which, in turn, will holistically enrich their plant-based health and wellbeing. “As PlantX continues to grow, we are committed to consistently improving the experience and satisfaction of our growing community,” reckoned Lorne Rapkin, PlantX’s Chief Executive Officer (“CEO”). “The XVIP membership plan includes an upgraded and more attractive range of exclusive benefits that increases value and boosts our customers’ enjoyment for PlantX products and services. Through XVIP, we hope to repay our customers’ loyalty more fully,” he added. Plant X also announced the completion of an oversubscribed non-brokered private placement of 52,296,660 units of the company at CAD$0.105 per unit. The approximate gross proceeds from the transaction stood at CAD$5,491,150, with the initial offer including the exercise of the company’s over-allotment option. Proceeds from the offering will be funneled into business development, general corporate purposes, and working capital. The securities issued in connection with the offering will be subject to a four-month hold period ending June 18, 2022, in accordance with applicable Canadian securities laws. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF